Glycosaminoglycans and semisynthetic sulfated polysaccharides: An overview of their potential application in treatment of patients with urrolithiasis

Urology

Volumn 50, Issue 2, 1997, Pages 173-183

  Cao, L C ^a   Boeve E R ^b   De Bruijn, W C ^b   Kok, D J ^b   De Water, R ^b   Deng, G ^b   Schroder F H ^b  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM OXALATE; CHONDROITIN 4 SULFATE; CHONDROITIN 6 SULFATE; DERMATAN SULFATE; G 871; G 872; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; HEPARIN; HYALURONIC ACID; KERATAN SULFATE; LENTINAN; PENTOSAN POLYSULFATE; POLYSACCHARIDE SULFATE; UNCLASSIFIED DRUG; VIVS NATRAL;

CLINICAL TRIAL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; DRUG URINE LEVEL; HUMAN; HYPEROXALURIA; NONHUMAN; PRIORITY JOURNAL; REVIEW; URINARY EXCRETION; UROLITHIASIS;

ANIMALS; GLYCOSAMINOGLYCANS; HUMANS; POLYSACCHARIDES; URINARY CALCULI;

EID: 0030842548     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(97)00227-6     Document Type: Review

References (111)

1. Boevé ER, Cao LC, Verkoelen CF, Romijn JC, de Bruijn WC, and Schröder FH: Glycosaminoglycans and other sulphated polysaccharides in calculogenesis of urinary stones. World J Urol 12: 43-48, 1994.
2. Cao LC, Boevé ER, and Schröder FH: The mechanisms of action of glycosaminoglycans (GAGs) in calcium oxalate stone prevention: a review. J Lithotripsy Stone Dis 3: 324-333, 1991.
3. Hesse A, Wuzel H, and Vahlensieck W: Significance of glycosaminoglycans for the formation of calcium oxalate stones. Am J Kidney Dis 17: 414-419, 1991.
4. Sallis JD: Glycosaminoglycans as inhibitors of stone formation [review]. Miner Electrolyte Metab 13: 273-277, 1987.
5. Hook M, Kjellen L, and Johansson S: Cell-surface glycosaminoglycans [review]. Annu Rev Biochem 53: 847-869, 1984.
6. Ofosu FA, Danishefsky I, and Hirsh J: Heparin and related polysaccharides: structure and activities. Ann NY Acad Sci 556: 1-449, 1987.
7. Lane DA, Björk I, and Lindahl U: Heparin and Related Polysaccharides. New York, Plenum Press, 1991, pp 1-365.
8. Hurst RE: Structure, function, and pathology of proteoglycans and glycosaminoglycans in the urinary tract. World J Urol 12: 3-10, 1994.
9. Chan VS, and Tan LMK: Determination of heparan sulphate in kidney tissues of patients with calcium nephrolithiasis. Urol Res 23: 339-342, 1995.
10. Iida S, Miyajima J, Suzuki K, Matsuoka K, Inoue M, and Noda S: Expression of heparan sulfate proteoglycan in rat kidney in the process of calcium oxalate formation, in Pak CYC, Resnick MI, and Preminger GM (Eds): Proceedings of the Eighth International Symposium on Urolithiasis, Dallas, Texas, September 29-October 2, 1996. Dallas, Millet the Printer, 1996, pp 554-555.
11. Parsons CL, Boychuk D, Jones S, Hurst R, and Callahan H: Bladder surface glycosaminoglycans: an epithelial permeability barrier. J Urol 143: 139-142, 1990.
12. Shum DK, Baylis C, and Scott JE: A micropuncture and renal clearance study in the rat of the urinary excretion of heparin, chondroitin sulphate and metabolic breakdown products of connective tissue proteoglycans. Clin Sci 67: 205-212, 1984.
13. Cao LC, Boevé ER, de Bruijn WC, Robertson WG, and Schröder FH: A review of new concepts in renal stone research. Scanning Microsc 7: 1049-1065, 1993.
14. Resnick MI, and Persky L: Summary of the National Institutes of Arthritis, Diabetes, Digestive and Kidney Diseases conference on urolithiasis: state of the art and future research needs. J Urol 153: 4-9, 1995.
15. Hess B, and Kok DJ: Nucleation, growth and aggregation of stone forming crystals, in Coe FL, Favus M, Pak CYC, Parks J, and Preminger G (Eds): Kidney Stones: Medical and Surgical Management. Philadelphia, Lippincott-Raven, 1996, pp 3-32.
16. Kok DJ, Papapoulos SE, Blomen LJ, and Bijvoet OL: Modulation of calcium oxalate monohydrate crystallization kinetics in vitro. Kidney Int 34: 346-350, 1988.
17. Kok DJ, Blomen LJ, Westbroek P, and Bijvoet OLM: Polysaccharide from coccoliths (CaCO3 biomineral). Influence on crystallization of calcium oxalate monohydrate. Eur J Biochem 158: 167-172, 1986.
18. Fellström B, Lindsjo M, Danielson BG, Karlsson FA, and Ljunghall S: Binding of glycosaminoglycan inhibitors to calcium oxalate crystals in relation to ionic strength. Clin Chim Acta 180: 213-220, 1989.
19. Kok DJ, Papapoulos SE, and Bijvoet OLM: Excessive crystal agglomeration with low citrate excretion in recurrent stone formers. Lancet 1: 1056-1058, 1986.
20. Kok DJ, Papapoulos SE, and Bijvoet OLM: Crystal agglomeration is a major element in calcium oxalate urinary stone formation. Kidney Int 37: 51-56, 1990.
21. Boevé ER, Cao LC, Deng G, de Bruijn WC, and Schröder FH: Effect of two new polysaccharides on growth, agglomeration and zeta potential of calcium phosphate crystals. J Urol 155: 368-373, 1996.
22. Cao LC, Boevé ER, Schröder FH, Robertson WG, Ketelaars GA, and de Bruijn WC: The effect of two new semi-synthetic glycosaminoglycans (G871, G872) on the zeta potential of calcium oxalate crystals and on growth and agglomeration. J Urol 147: 1643-1646, 1992.
23. Cao LC, Boevé ER, de Bruijn WC, Deng G, van Miert P, Verkoelen CF, Romijn JC, and Schröder FH: Effect of glycosaminoglycans and semi-synthetic sulphated polysaccharides on calcium oxalate crystallization in vitro: a comparative study, in Rao PN, Kavanaph JP, and Tiselius HG (Eds): Proceedings of the Fifth European Symposium on Urolithiasis, Manchester, UK, April 21-23, 1994, pp 283-285.
24. Cao LC, Feng G, Boevé ER, de Bruijn WC, de Water R, Verkoelen CF, Romijn JC, and Schröder FH: Zeta potential measurement and particle size analysis for a better understanding of urinary inhibitors of calcium oxalate crystallization. Scanning Microsc 10: 401-414, 1996.
25. Ryall RL: Macromolecule in stones: promiscuous players, inadequate protectors or malevolent provocateurs?, in Tiselius HG (Ed): Proceedings of the Sixth European Symposium on Urolithiasis, Stockholm, Sweden, June 8-10, 1995. Edsbruk, Akademitryck AB, 1995, pp 9-15.
26. Finlayson B, and Reid F: The expectation of free and fixed particles in urinary stone disease. Invest Urol 15: 442-448, 1978.
27. Kok DJ, and Khan SR: Calcium oxalate nephrolithiasis, a free or fixed particle disease. Kidney Int 46: 847-854, 1994.
28. de Bruijn WC, Boevé ER, van Run PR, van Miert PP, Romijn JC, Verkoelen CF, Cao LC, and Schröder FH: Etiology of experimental calcium oxalate monohydrate nephrolithiasis in rats. Scanning Microsc 8: 541-550, 1994.
29. Ebisuno S, Kohjimoto Y, Tamura M, and Ohkawa T: Adhesion of calcium oxalate crystals to Madin-Darby canine kidney cells and some effects of glycosaminoglycans or cell injuries. Eur Urol 28: 68-73, 1995.
30. Ebisuno S, Tamura M, Kohijmoto Y, and Ohkawa T: The effects of human urine on the adhesion of calcium oxalate crystals to MDCK cells, in Pak CYC, Resnick MI, and Preminger GM (Eds): Proceedings of the Eighth International Symposium on Urolithiasis, Dallas, Texas, September 29-October 2, 1996. Dallas, Millet the Printer, 1996, pp 317-319.
31. Lieske JC, Walsh-Reitz MM, and Toback FG: Calcium oxalate monohydrate crystals are endocytosed by renal epithelial cells and induce proliferation. Am J Physiol 262: F622-F630, 1992.
32. Boevé ER, Ketelaars GA, Vermeij M, Cao LC, Schröder FH, and de Bruijn WC: An ultrastructural study of experimentally induced microliths in rat proximal and distal tubules. J Urol 149: 893-899, 1993.
33. de Bruijn WC, Boevé ER, van Run PR, van Miert PP, de Water R, Romijn JC, Verkoelen CF, Cao LC, and Schröder FH: Etiology of calcium oxalate nephrolithiasis in rats. I. Can this be a model for human stone formation? Scanning Microsc 9: 103-114, 1995.
34. de Bruijn WC, Boevé ER, van Run PR, van Miert PP, de Water R, Romijn JC, Verkoelen CF, Cao LC, van't Noordende JM, and Schröder FH: Etiology of calcium oxalate nephrolithiasis in rats. II. The role of the papilla in stone formation. Scanning Microsc 9: 115-125, 1995.
35. Gill WB, Jones KW, and Ruggiero KJ: Protective effects of heparin and other sulfated glycosaminoglycans on crystal adhesion to injured urothelium. J Urol 127: 152-154, 1982.
36. Pantazopoulos D, Karagiannakos P, Sofras F, Kostakopoulos A, Deliveliotis C, and Dimopoulos C: Effect of drugs on crystal adhesion to injured urothelium. Urology 36: 255-259, 1990.
37. Parsons CL, Danielson B, and Feldstrom B: Inhibition of sodium urate crystal adherence to bladder surface by polysaccharide. J Urol 134: 614-616, 1985.
38. Nishio S, Abe Y, Wakatsuki A, Iwata H, Ochi K, Takeuchi M, and Matsumoto A: Matrix glycosaminoglycan in urinary stones. J Urol 134: 503-505, 1985.
39. Suzuki K, Mayne K, Doyle IR, and Ryall RL: Urinary glycosaminoglycans are selectively included into calcium oxalate crystals precipitated from whole human urine. Scanning Microsc 8: 523-530, 1994.
40. Suzuki K, and Ryall RL: The effect of heparan sulphate on the crystallization of calcium oxalate undiluted, ultrafiltered human urine. Br J Urol 78: 15-21, 1996.
41. Lieske JC, Leonard R, and Toback FG: Adhesion of calcium oxalate monohydrate crystals to renal epithelial cells is inhibited by specific anions. Am J Physiol 268: F604-F612, 1995.
42. Lieske JC, and Toback FG: Regulation of renal epithelial cell endocytosis of calcium oxalate monohydrate crystals. Am J Physiol 264: F800-F807, 1993.
43. Verkoelen CF, Romijn JC, de Bruijn WC, Boevé ER, Cao LC, and Schröder FH: Association of calcium oxalate monohydrate crystals with MDCK cells. Kidney Int 48: 129-138, 1995.
44. Verkoelen CF, Romijn JC, Cao LC, Boevé ER, de Bruijn WC, and Schröder FH: Crystal-cell interaction inhibition by polysaccharides. J Urol 155: 749-752, 1996.
45. Menter JM, Hurst RE, Nakamura N, and West SS: Thermodynamics of mucopolysaccharide-dye binding. III. Thermodynamics and cooperativity of the acridine orange-heparin system. Biopolymers 18: 493-505, 1979.
46. Pass G, Philips GO, Wedlock DJ, and Morley RG: Interaction of sulfated polysaccharides with counter-ions, in Schweiger RG (Ed): Carbohydrate Sulfates. Washington, DC, American Chemical Society, 1978, pp 259-281.
47. Nathan C, and Sporn M: Cytokines in context. J Cell Biol 113: 981-986, 1991.
48. Williams HE, and Wandzilak TR: Oxalate synthesis, transport and the hyperoxaluric syndromes. J Urol 141: 742-749, 1989.
49. Baggio B, Gambaro G, Marchini F, Cicerello E, and Borsatti A: Raised transmembrane oxalate flux in red blood cells in idiopathic calcium oxalate nephrolithiasis. Lancet 2: 12-13, 1984.
50. Borsatti A: Calcium oxalate nephrolithiasis: defective oxalate transport. Kidney Int 39: 1283-1298, 1991.
51. Gambaro G, and Baggio B: Idiopathic calcium oxalate nephrolithiasis: a cellular disease. Scanning Microsc 6: 247-254, 1992.
52. Baggio B, Marzaro G, Gambaro G, Marchini F, Williams HE, and Borsatti A: Glycosaminoglycan content, oxalate self-exchange and protein phosphorylation in erythrocytes of patients with "idiopathic" calcium oxalate nephrolithiasis. Clin Sci 79: 113-116, 1990.
53. Baggio B, Gambaro G, Marchini F, Marzaro G, Williams HE, and Borsatti A: Correction of erythrocyte abnormalities in idiopathic calcium-oxalate nephrolithiasis and reduction of urinary oxalate by oral glycosaminoglycans. Lancet 338: 403-405, 1991.
54. Baggio B, Gambaro G, Marzaro G, Marchini F, Borsatti A, and Crepaldi G: Effects of the oral administration of glycosaminoglycans on cellular abnormalities associated with idiopathic calcium oxalate nephrolithiasis. Eur J Clin Pharmacol 40: 237-240, 1991.
55. Subha K, Baskar R, and Varalakshmi P: Biochemical changes in kidneys of normal and stone forming rats with sodium pentosan polysulphate. Biochem Int 26: 357-365, 1992.
56. Calo L, Wandzilak TR, Davis PA, Borsatti A, and Williams HE: Effect of second messenger systems on oxalate uptake in renal epithelial cells. Urol Res 23: 89-94, 1995.
57. Shum DKY, Law SSY, and Liong E: Glycosaminoglycan control of oxalate transport across cultured renal cells, in Tiselius HG (Ed): Proceedings of the Sixth European Symposium on Urolithiasis, Stockholm, June 8-10, 1995. Edsbruk, Akademitry AB, 1995, pp 82-83.
58. Khan SR, Shevock PN, and Hackett RL: Acute hyperoxaluria, renal injury and calcium oxalate urolithiasis. J Urol 147: 226-230, 1992.
59. Menon M, and Koul H: Clinical review 32: calcium oxalate nephrolithiasis [review]. J Clin Endocrinol Metab 74: 703-707, 1992.
60. Subha K, and Varalakshmi P: Alterations in some risk factors and urinary enzymes in urolithiatic rats treated with sodium pentosan polysulphate. Biochem Mol Biol Int 29: 271-280, 1993.
61. Boevé ER, Cao LC, Schröder FH, Ketelaars GAM, Vermey M, and de Bruijn WC: The influence of exogenous glycosaminoglycans on the experimental induction of microliths in rats. Urol Res 18: 62, 1990.
62. Kok DJ: Free and fixed particle mechanism, a review. Scanning Electron Microsc 10: 471-486, 1996.
63. Kok DJ: Intratubular crystallization events. World J Urol 1997 (in press).
64. Sidhu H, Hemal AK, Thind SK, Nath R, and Vaidyanathan S: Comparative study of 24-hour urinary excretion of glycosaminoglycans by renal stone formers and healthy adults. Eur Urol 16: 45-47, 1989.
65. Subha K, and Varalakshmi P: Effect of sodium pentosan polysulphate on tissue lipids in control and glycollate treated rats. Pharmacol Res 27: 289-297, 1993.
66. Gambaro G, Cicerello E, Mastrosimone S, Lavagnini T, and Baggio B: High urinary excretion of glycosaminoglycans: a possible marker of glomerular involvement in diabetes. Metabolism 38: 419-420, 1989.
67. Gambaro G, Cavazzana AO, Luzi P, Piccoli A, Borsatti A, Crepaldi G, Marchi E, Venturini AP, and Baggio B: Glycosaminoglycans prevent morphological renal alterations and albuminuria in diabetic rats. Kidney Int 42: 285-291, 1992.
68. Alkibay T, Karabas O, Hizel N, and Bozkirli I: Urinary glycosaminoglycan excretion following extracorporeal shock wave lithotripsy. Int Urol Nephrol 25: 321-326, 1991.
69. Karlsen SJ, Smevik B, Klingenberg-Lund K, and Berg KJ: Do extracorporeal shock waves affect urinary excretion of glycosaminoglycans? Br J Urol 67: 24-28, 1991.
70. Karlsen SJ, and Berg KJ: Acute changes in kidney function following extracorporeal shock wave lithotripsy for renal stones. Br J Urol 67: 241-245, 1991.
71. Winter P, Ganter K, Leppin U, Schoeveich G, and Hesse A: Glycosaminoglycans in urine and extracorporeal shock wave lithotripsy. Urol Res 23: 401-405, 1995.
72. Butt AJ: Role of protective urinary colloids in prevention of lithiasis. J Urol 67: 450-459, 1952.
73. Robertson WG, Peacock M, and Nordin BE: Inhibitors of the growth and aggregation of calcium oxalate crystals in vitro. Clin Chim Acta 43: 31-37, 1973.
74. Robertson WG, Peacock M, Heyburn PJ, Marshall DH, and Clark PB: Risk factors in calcium stone disease of the urinary tract. Br J Urol 50: 449-454, 1978.
75. Conte A, Roca P, Genestar C, and Grases F: Uric acid and its relationship with glycosaminoglycans in normal and stone-former subjects. Nephron 52: 162-165, 1989.
76. Gianotti M, Genestar C, Palou A, Pons A, Conte A, and Grases F: Investigation of GAGs on 24-hour and 2-hour urines from calcium oxalate stone formers and healthy subjects. Int Urol Nephrol 21: 281-288, 1989.
77. Hwang TI, Preminger GM, Poindexter J, and Pak CY: Urinary glycosaminoglycans in normal subjects and patients with stones. J Urol 139: 995-997, 1988.
78. Martin X, Werness PG, Bergert JH, and Smith LH: Pentosan polysulfate as an inhibitor of calcium oxalate crystal growth. J Urol 132: 786-788, 1984.
79. Michelacci YM, Glashan RQ, and Schor N: Urinary excretion of glycosaminoglycans in normal and stone forming subjects. Kidney Int 36: 1022-1028, 1989.
80. Nesse A, Garbossa G, Romero MC, Bogado CE, and Zanchetta JR: Glycosaminoglycans in urolithiasis. Nephron 62: 36-39, 1992.
81. Nikkila MT: Urinary glycosaminoglycan excretion in normal and stone-forming subjects: significant disturbance in recurrent stone formers. Urol Int 44: 157-159, 1989.
82. Akinci M, Esen T, Kocak T, Ozsoy C, and Tellaloglu S: Role of inhibitor deficiency in urolithiasis. I. Rationale of urinary magnesium, citrate, pyrophosphate and glycosaminoglycan determinations. Eur Urol 19: 240-243, 1991.
83. Baba S, Nakazawa K, Odajima K, Fujioka T, and Nakamura H: Observation on urinary glycosaminoglycan excretion in patients with urinary calculus in relation to the nature of organic matrix of calculi. Nippon Hinyokika Gakkai Zasshi 74: 608-615, 1983.
84. Caudarella R, Stefani F, Rizzoli E, Malavolta N, and D'Antuono G: Preliminary results of glycosaminoglycans excretion in normal and stone forming subjects: relationship with uric acid excretion. J Urol 129: 665-667, 1983.
85. Fellström B, Lindsjo M, Danielson BG, Ljunghall S, and Wikström B: Binding of glycosaminoglycans to sodium urate and uric acid crystals. Clin Sci 71: 61-64, 1986.
86. Hesse A, Wuzel H, and Vahlensieck W: The excretion of glycosaminoglycans in the urine of calcium-oxalate-stone patients and healthy persons. Urol Int 41: 81-87, 1986.
87. Ryall RL, Harnett RM, and Marshall VR: The effect of urine, pyrophosphate, citrate, magnesium and glycosaminoglycans on the growth and aggregation of calcium oxalate crystals in vitro. Clin Chim Acta 112: 349-356, 1981.
88. Samuell CT: A study of glycosaminoglycan excretion in normal and stone-forming subjects using a modified cetylpyridinium chloride technique. Clin Chim Acta 117: 63-73, 1981.
89. Trinchieri A, Mandressi A, Luongo P, Rovera F, and Longo G: Urinary excretion of citrate, glycosaminoglycans, magnesium and zinc in relation to age and sex in normal subjects and in patients who form calcium stones. Scand J Urol Nephrol 26: 379-386, 1992.
90. al-Hakim A, and Linhardt RJ: Electrophoresis and detection of nanogram quantities of exogenous and endogenous glycosaminoglycans in biological fluids. Appl Theor Electrophor 1: 305-312, 1991.
91. Takagaki K, Takeda Y, Nakamura T, Daidouji K, Narita H, and Endo M: Analysis of glycosaminoglycans by high-performance liquid chromatography. J Biochem Biophys Methods 28: 313-320, 1994.
92. Callahan HJ, Shupp-Byrne D, Pizzo M, Parsons CL, and Mulholland SG: The production of antibodies to pentosanpolysulfate (ELMIRON, SP-54). J Immunol Methods 136: 53-59, 1991.
93. Kongtawelert P, and Ghosh P: A monoclonal antibody that recognizes 2,3-, 2,6-, and 4,6-disulphate ester ring substitution in pyranose-containing polysaccharides. Its production, characterization and application for the quantitation of pentosan polysulphate, dextran sulphate, glycosaminoglycan polysulphate and chondroitin sulphate E. J Immunol Methods 126: 39-49, 1990.
94. Danielson BG, Fellström B, and Wikstrôm B: Glycosaminoglycans as inhibitors of renal stone formation, in Walker VR, Sutton RAL, Cameron ECB, Pak CYC, and Robertson WG (Eds): Urolithiasis. New York, Plenum, 1989, pp 101-104.
95. Fellström B, Danielson BG, Eriksson H, Odlind B, and Tengblad A: Pentosan polysulphate (Elmiron): pharmacokinetics and effects on the urinary inhibition of crystal growth. Fortschr Urol Nephrol 25: 340-344, 1986.
96. Fukatani T: Studies on sodium pentosan polysulphate (SPP) therapy on the urinary stone disease. Experimental studies on the calcium oxalate crystallization and the effects in healthy subjects. Nippon Hinyokika Gakkai Zasshi 82: 246-253, 1991.
97. Fellström B, Backman U, Danielson B, and Wikström B: Treatment of renal calcium stone disease with the synthetic glycosaminoglycan pentosan polysulphate. World J Urol 12: 52-54, 1994.
98. Gohel MDI, and Shum DKY: Crystal-suppressive modulators of separated urinary polyanions, in Tiselius HG (Ed): Proceedings of the Sixth European Symposium on Urolithiasis, Stockholm, June 8-10, 1995. Edsbruk, Akademitry AB, 1995, pp 84-85.
99. Foye WO: Sulfur compounds in therapy: radiation-protective agents, amphetamines, and mucopolysaccharide sulfation. Ann Pharmacother 26: 1144-1147, 1992.
100. 14C-oxalate, in Pak CYC, Resnick MI, and Preminger GM (Eds): Proceedings of the Eighth International Symposium on Urolithiasis, Dallas, Texas, September 29-October 2, 1996. Dallas, Millet the Printer, 1996, pp 245-246.
101. Wright RJ, and Hodgkinson A: Oxalic acid, calcium, and phosphorus in the renal papilla of normal and stone forming rats. Invest Urol 9: 369-375, 1972.
102. Hautmann RE, Lehman A, and Osswald H: Intrarenal calcium and oxalate concentration gradients in healthy and stone forming kidneys, the renal papilla as the primary nucleation site, in Smith LH, Robertson WG, and Finlayson B (Eds): Urolithiasis, Clinical and Basic Research. New York, Plenum, 1980, pp 509-515.
103. Buck AC, and Reis-Santos JM: Animal model of stone disease, in Wickham JEM, and Buck AC (Eds): Renal Tract Stone - Metabolic Basis and Clinical Practice. London, Churchill Livingstone, 1990, pp 149-161.
104. Cao LC, Deng G, Boevé ER, de Bruijn WC, Verkoelen CF, Romijn JC, and Schröder FH: Does oxalate interfere with the role of glycosaminoglycans and semi-synthetic sulphated polysaccharides in calcium oxalate crystallization? Eur Urol 31: 485-492, 1997.
105. Burgess NA, Reynolds TM, William N, Pathy A, and Smith S: Evaluation of four animal model of intrarenal calcium deposition and assessment of the influence of dietary supplementation with essential fatty acid on calcification. Urol Res 23: 239-242, 1995.
106. Hansen NM, Felix R, Bisaz S, and Fleisch H: Aggregation of hydroxyapatite crystals. Biochim Biophys Acta 451: 549-559, 1976.
107. Bowyer RC, Brockis JG, and McCulloch RK: Glycosaminoglycans as inhibitors of calcium oxalate crystal growth and aggregation. Clin Chim Acta 95: 23-28, 1979.
108. Norman RW, Scurr DS, Robertson WG, and Peacock M: Inhibition of calcium oxalate crystallisation by pentosan polysulphate in control subjects and stone formers. Br J Urol 56: 594-598, 1984.
109. Kohri K, Garside J, and Blacklock NJ: The effect of glycosaminoglycans on the crystallisation of calcium oxalate. Br J Urol 63: 584-590, 1989.
110. Miyazawa K, Suzuki K, and Tsugawa R: The quantitative study of inhibitory effect of pentosan polysulfate and chlorophyllin on the experimental calcium oxalate stone. Nippon Hinyokika Gakkai Zasshi 80: 861-869, 1989.
111. Grases F, Costa-Bauza A, March JG, and Masarova L: Glycosaminoglycans, uric acid and calcium oxalate urolithiasis. Urol Res 19: 375-380, 1991.